Dr. Reddys Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion, in the United States
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion, in the...
Business Wire
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, July 31, 2026 Investigation focuses on RDY losses after Dr. Reddy's disclosed a 2.4 billion provision tied to...
PR Newswire
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddys Laboratories (RDY)
RDY shareholders saw Dr. Reddys Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a 2.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision...
Business Wire
RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories
RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories PR Newswire NEW YORK, July 27, 2026 RDY...
PR Newswire
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY) Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY) PR Newswire...
PR Newswire
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
RDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.
Zacks
Dr. Reddy's Laboratories Q1 Net Profit Drops As Revenue Slips, Expenses Climb
(RTTNews) - Dr. Reddy's Laboratories Limited (RDY, 500124, DRREDDY), a major Indian pharmaceutical company, on Thursday posted a decline in net income for the first quarter, hurt by decreased revenue and increased expenses...
Nasdaq News: Markets
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call
Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below.
Benzinga APIs provide real-time access to earnings callread more...
Benzinga
Dr. Reddys Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddys Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial...
Business Wire
Dr. Reddys Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif, in the United States
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio and...
Business Wire